Janssen seeks European marketing authorisation for subcutaneous (under the skin) daratumumab (Darzalex®)
The pharmaceutical company Janssen, who produce a range of myeloma medicines, have today announced their application to the European Medicines Agency (EMA) for a license extension for daratumumab. This license extension, if approved by the EMA, would allow the use of subcutaneous (under the skin) daratumumab (Darzalex®) in myeloma patients.